Vaccinex, Inc. (VCNX) |
|
1.06 -0.02 (-1.85%)
|
06-29 17:49 |
|
Open: |
1.05 |
Pre. Close: |
1.08 |
|
High:
|
1.1 |
Low:
|
1.03 |
|
Volume:
|
50,851 |
Market Cap:
|
45(M) |
|
|
|
|
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.1 - 1.11 |
1.11 - 1.11 |
|
Low:
|
1.01 - 1.02 |
1.02 - 1.03 |
|
Close:
|
1.05 - 1.06 |
1.06 - 1.07 |
|
Technical analysis |
as of: 2022-06-29 4:58:23 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.43 One year: 1.6 |
| Support: |
Support1: 1 Support2: 0.83 |
| Resistance: |
Resistance1: 1.22 Resistance2: 1.37 |
| Pivot: |
1.12  |
| Moving Average: |
MA(5): 1.09  MA(20): 1.17
MA(100): 1.27 MA(250): 1.64 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 21.9 %D(3): 26.3 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 2.68 Low: 0.89 |
| Average Vol(K): |
3-Month: 110 (K) 10-Days: 95 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VCNX ] has closed above bottom band by 26.9%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 28 Jun 2022
BioVie : Regulation FD Presentation - Form 8-K - Marketscreener.com
Thu, 09 Jun 2022
Is Vaccinex Inc (VCNX) a Laggard in the Healthcare Sector? - InvestorsObserver
Wed, 01 Jun 2022
Is Vaccinex Inc (VCNX) Stock a Bad Value? - InvestorsObserver
Mon, 25 Apr 2022
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery - GlobeNewswire
Thu, 31 Mar 2022
Vaccinex Reports 2021 Financial Results and Provides Corporate Update - GlobeNewswire
Wed, 09 Mar 2022
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
2.618e+007 (%) |
|
% Held by Institutions
|
12 (%) |
|
Shares Short
|
818 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.232e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
498.8 |
|
Return on Equity (ttm)
|
-130.5 |
|
Qtrly Rev. Growth
|
900000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-790.26 |
|
EBITDA (p.s.)
|
-1.37797e+007 |
|
Qtrly Earnings Growth
|
-1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-25 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
3.2 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
564830 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
